Robert W. Baird Forecasts Strong Price Appreciation for Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise (NASDAQ:AXON) had its price objective raised by Robert W. Baird from $440.00 to $460.00 in a research report report published on Monday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

AXON has been the subject of a number of other reports. Jefferies Financial Group began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective for the company. Bank of America initiated coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target for the company. Northland Securities raised their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Craig Hallum upped their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Needham & Company LLC increased their price target on Axon Enterprise from $400.00 to $525.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus price target of $392.85.

Axon Enterprise Trading Up 2.0 %

Shares of AXON stock opened at $468.75 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company has a market cap of $35.42 billion, a price-to-earnings ratio of 123.68, a PEG ratio of 10.99 and a beta of 0.94. Axon Enterprise has a 1 year low of $212.88 and a 1 year high of $471.00. The firm has a fifty day moving average price of $409.39 and a 200-day moving average price of $344.81.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. Axon Enterprise’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.80 earnings per share. As a group, equities analysts predict that Axon Enterprise will post 1.79 earnings per share for the current year.

Insider Activity at Axon Enterprise

In related news, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the sale, the director now owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Patrick W. Smith sold 80,300 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the sale, the chief executive officer now owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the sale, the director now owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 369,172 shares of company stock valued at $136,270,842. 5.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently made changes to their positions in AXON. Avantax Advisory Services Inc. grew its holdings in Axon Enterprise by 0.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after purchasing an additional 40 shares during the last quarter. Foundations Investment Advisors LLC bought a new position in shares of Axon Enterprise during the third quarter valued at approximately $221,000. Sequoia Financial Advisors LLC grew its stake in shares of Axon Enterprise by 4.9% during the third quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock valued at $690,000 after buying an additional 81 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Axon Enterprise in the first quarter worth approximately $931,000. Finally, Zurich Insurance Group Ltd FI lifted its stake in shares of Axon Enterprise by 1.9% during the 2nd quarter. Zurich Insurance Group Ltd FI now owns 205,015 shares of the biotechnology company’s stock worth $60,324,000 after acquiring an additional 3,832 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.